- Home
- RBOT vs TPST Comparison
RBOT vs TPST Comparison
Compare RBOT & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RBOT | TPST |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9M | 15.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RBOT | TPST |
|---|---|---|
| Price | $2.59 | $2.89 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 2 |
| Target Price | $7.00 | ★ $12.50 |
| AVG Volume (30 Days) | ★ 146.2K | 74.3K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.81 | $2.75 |
| 52 Week High | $18.75 | $13.26 |
Technical Indicators
Market Signals| Indicator | RBOT | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 51.26 | 32.97 |
| Support Level | $2.40 | $2.80 |
| Resistance Level | $2.76 | $3.04 |
| Average True Range (ATR) | 0.26 | 0.17 |
| MACD | 0.13 | 0.17 |
| Stochastic Oscillator | 80.00 | 42.04 |
Price Performance
Historical ComparisonAbout RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.